Kidney diseases

Together, we dare to transform lives, by applying our long-standing expertise in immunology to address unmet needs across the spectrum of kidney and kidney-related diseases.

Challenge

More than 850 million people worldwide are affected by kidney diseases and the impact on those affected and healthcare systems is severely under-recognised.1 Although progress has been made in treatment and management, prevalence is rising and kidney diseases are predicted to become the fifth leading cause of lives lost by 2040.1,2 We want to change this.

Focus

For 20 years, we have combined innovation, scientific expertise and commitment to patients to address unmet needs in kidney diseases. Applying our expertise in immunology, we aim to continue delivering meaningful value for those affected, healthcare systems and society. 

Our industry-leading pipeline, informed and guided by the needs of patients, spans lupus nephritis, membranous nephropathy, immunoglobulin A nephropathy, atypical haemolytic uraemic syndrome, childhood-onset idiopathic nephrotic syndrome and systemic lupus erythematosus, an autoimmune disease that can lead to lupus nephritis.

References

  1. Jager KJ, et al. A single number for advocacy and communication-worldwide more than 850 million individuals have kidney diseases. Kidney Int. 2019;96:1048-1050

  2. Nature Reviews Nephrology. 2024;20:473–485

Meet the Nephrology team

Stephen Wright

Franchise Lead for Rheumatology & Nephrology

Jay Garg

Global Head of Nephrology, Rheumatology & Cardiovascular

Ted Omachi

Global Development Lead, Immunology

Pippa Postins

Global Integrated Strategy Leader, Nephrology & Rheumatology

Cases in detail

Videos

The pursuit for change

Hear from Pippa Postins, Global Integrated Strategy Leader, Nephrology & Rheumatology and Michael Oberreiter, Head of Global Access at Roche, about Roche’s ambitious goals for kidney and kidney-related diseases.

More focus areas

View all focus areas

Discover more